Senores Pharmaceuticals Limited has informed the Exchange regarding Investor Presentation
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals reported strong FY26 results with total income of Rs. 664 crores, up 62% YoY from Rs. 410 crores. EBITDA surged 96% to Rs. 200 crores with margins expanding 527 basis points to 30.1%. PAT more than doubled to Rs. 122 crores with PAT margin at 18.3%. The company has 51 approved ANDAs covering 151 strengths, with 30 ANDAs yet to be launched and 27 more under development. Key acquisitions include 51% stake in Zoraya Pharmaceuticals (USA) and 75% stake in Apnar Pharmaceuticals. A new 70% JV called Amerisyn was formed to enter the US federal and defense pharmaceutical market. Branded generics revenue grew 385% YoY, while emerging markets grew 13%. Operating cash flow improved significantly to Rs. 75 crores.
The company is demonstrating strong operational execution with margin expansion across all segments. The expansion into US federal market via Amerisyn JV and the growing ANDA portfolio provide multiple growth levers for the future. Investors should note the improving cash flow and profitability metrics.